KVUE

Kenvue Inc presents a distinctive consumer products profile characterized by defensive attributes and mixed operational signals. The company's beta of 0.55 positions it as one of the more insulated equities within the consumer staples complex, while the current price of $17.18 represents a 29.5% decline from the 52-week high of $24.36, suggesting substantial multiple compression since the mid-2024 peak.

Systematic screening highlights several fundamental strengths:

• The gross margin of 58.85% demonstrates meaningful pricing power and product differentiation within branded consumer health categories, supporting operational resilience against input cost volatility.
• ROE of 15.18% indicates effective capital deployment relative to shareholder equity, particularly noteworthy given the 0.79 debt-to-equity ratio that maintains balance sheet flexibility.
• EPS expansion of 53.73% year-over-year contrasts sharply with essentially flat revenue growth of -0.07%, signaling margin improvement and operational efficiency gains through the post-spinoff transition period.

The model flags two material risk factors. The current ratio of 0.96 sits below the conventional 1.0 threshold, indicating potential near-term liquidity constraints that warrant monitoring through upcoming reporting cycles. Additionally, the absence of reported free cash flow per share data limits comprehensive cash generation analysis during this early stage as an independent public entity.

The P/E ratio of 20.25 and P/S multiple of 2.15 position KVUE at a valuation discount relative to beauty-focused peer EL, though fundamental screening suggests different category exposures warrant distinct analytical frameworks. The combination of defensive beta characteristics and improving profitability metrics differentiates KVUE within the broader consumer products landscape.